This is supported by evidence that SGLT2 inhibitors have neuroprotective properties in patients and animals with T2D, such as improving impaired cognitive function (Hayden et al., 2019; Hierro‐Bujalance et al., 2020; Lin et al., 2014), and have further applications in many neurodegenerative diseases such as AD, PD, Huntington's disease, epilepsy and cerebral ischaemia (Arab et al., 2021; El‐Sahar et al., 2020; Hierro‐Bujalance et al., 2020; Lin et al., 2014). Here, SLC5A2 is linked to Parkinson disease.